Medtronic received the following information obtained from the journal article entitled: use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers increases the risk of postoperative acute kidney injury after elective endovascular abdominal aortic aneurysm repair xiang et al, chinese medical journal 2022;135(23) doi: 10.1097/cm9.0000000000002352 a2: mean age a3: mean gender d6a: exact date of implant unknown g2: citation: authors: yuwei xiang, yang liu, jichun zhao, bin huang, zhoupeng wu, xiyang chen.Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers increases the risk of postoperative acute kidney injury after elective endovascular abdominal aortic aneurysm repair.Chinese medical journal 135(23) 2022.10.1097/cm9.0000000000002352 earliest date of publication used for date of event no unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.Without return of the product no definitive conclusion can be made regarding the clinical observations.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
Additional information received; it was reported that the acute kidney injury (aki) mentioned in the article is not related to the endurant stent grafts.The postoperative deaths mentioned in the article were not related to the endurant stent graft or the index procedure itself.The main factors of aki or death mentioned in the article are related to the patient's own renal function combined with intraoperative angiography.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|